deltatrials
Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07228663

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (HIPSTER-Pilot)

Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

Sponsor: Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

Conditions Cardiovascular Prevention Hip Fracture Surgery Venous Thromboembolism (VTE)
Interventions Direct Oral Anticoagulant (DOAC) Fondaparinux Low-molecular weight heparin rivaroxaban and ASA
Updated 1 time since 2025 Last updated: Nov 13, 2025 Started: Dec 1, 2025 Primary completion: Jul 1, 2027 Completion: Dec 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cardiovascular Prevention and Hip Fracture Surgery, this trial is actively recruiting participants. The trial is conducted by Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network and has accumulated 1 data snapshot since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Dec 2025 – present · 9 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
  • International Network of VENous Thromboembolism Clinical Research Networks
  • McMaster University
Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations